Hormonal medication in medically assisted reproduction: a systematic review of assessments from patients

Abstract

is a midwife and postdoctoral research fellow of the Research Foundation Flanders (Belgium). Her PhD thesis focused on 'Bridging the gap between evidence based and patient-centered fertility and endometriosis care'. Eline coordinates the Nurses and Midwives Certification Committee of the European Society for Human Reproduction and Embryology (ESHRE).

Migraine and infertility, merging concepts in women's reproductive health: A narrative review

“…Several studies demonstrate a treatment‐related mild headache in response to medications used for HPO axis downregulation including GnRH antagonists and agonists and medications used for ovarian stimulation. In an analysis of 35 clinical trials, it was estimated that headache occurred in 11% to 19% of patients treated with various ART protocols 48 . In a study of 45 healthy women treated with ganirelix, 49,50 the most common side effect was mild headache which occurred in 71% of patients (32/45) 51 .…”

“…Mild headache has also been reported during the first 2 weeks after administration in patients treated with luteinizing hormone‐releasing hormone (buserelin) and GnRH agonists (goserelin) 52 . During ovarian stimulation, headache can occur in 7.1% to 15% of patients receiving follitropin alpha 48–52 . Likewise, in patients receiving clomiphene, 3% to 20% had mild headache and nausea 53–57 …”

“…In an analysis of 35 clinical trials, it was estimated that headache occurred in 11% to 19% of patients treated with various ART protocols. 48 In a study of 45 healthy women treated with ganirelix, 49,50 the most common side effect was mild headache which occurred in 71% of patients (32/45). 51 Mild headache has also been reported during the first 2 weeks after administration in patients treated with luteinizing hormone-releasing hormone (buserelin) and GnRH agonists (goserelin).…”

“…52 During ovarian stimulation, headache can occur in 7.1% to 15% of patients receiving follitropin alpha. [48][49][50][51][52] Likewise, in patients receiving clomiphene, 3% to 20% had mild headache and nausea. [53][54][55][56][57] While reports of more severe new onset headache disturbance during IVF are rare, 58 there is one case report of new onset clusterlike headache attacks in a patient undergoing IVF which occurred during progesterone treatment for luteal phase support.…”

An evaluation of the use and handling errors of currently available recombinant human follicle-stimulating hormone pen injectors by women with infertility and fertility nurses

“…Patient preference is of growing importance for fertility treatment owing to the emphasis on patient-centered care and treatment individualization [11,12,13,14,15,16]. Studies evaluating which aspects of pen injectors are most important to patients, and also how patients approach processes related to the use of pen injectors, are of interest and should employ the most optimal methods to compare different devices from the patient perspective.…”